

InnoCare Pharma
2025H1 Results

Stock Code: 09969.HK, 688428.SH

August 19, 2025

Disclaimer

These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the "Company") or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

The information or opinions contained in these materials has not been independently verified. No representation or warranty, whether expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information and opinions contained in these materials are provided as of the date of the presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. The Company, any of its affiliates, directors, supervisors, senior managers, officers, employees, advisers and their respective representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from or in reliance upon any information contained or presented in or derived from these materials or otherwise arising in connection with these materials.

These materials contain statements that reflect the Company's current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company's operations and businesses and on factors beyond the Company's control, and are subject to significant risks and uncertainties, and, accordingly, the actual results may differ materially from these forward-looking statements. You should not place undue reliance on any of such forward-looking information. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that emerge subsequent to such dates.

Our Mission & Vison:
Science Drives Innovation for the Benefit of Patients

To Become
a **Global Biopharmaceutical Leader**
that Develops and Delivers
Innovative Therapies for Patients **Worldwide**

Cancer

Autoimmune

Our Therapeutic Focus

Celebrating Landmark Approvals of Orelabrutinib and Tafasitimab

Key Achievements in 2025H1

Robust Commercial Acceleration & Solid Financial Foundation

- Total revenue reached **RMB 731 million**, representing a **yoy increase of 74.3%**
- Drug sales achieved **RMB 641 million** with **53.5% yoy growth**
- **Net loss** for the first half of 2025 significantly narrowed to **RMB 35.6 million**, representing a **yoy decrease of 86.7%**
- **Strong cash position of ~RMB 7.7 billion**

Diversified Product Portfolio & Multiple PhIII Studies to Address Unmet Medical Needs

- **Orelabrutinib 1L CLL/SLL NDA approved in China** and other indications NDA submitted in overseas
- **Tafasitimab BLA for r/r DLBCL approved in China** with commercial launch planned next month
- **Zurletrectinib (ICP-723) NDA accepted and under priority review**
- **Mesutoclax (ICP-248)**
  - Combo with Orelabrutinib entered into **Ph3 registrational trial for 1L CLL/SLL-FDT**; patient enrollment ongoing
  - Approved to initiate **registrational study for BTKi treated MCL**; the first BCL-2 inhibitor in China to receive **Breakthrough Therapy Designation (BTD)**
  - **1L AML** dose expansion in CHN and global
  - **MDS** global study initiated
- **Orelabrutinib in Autoimmune Diseases**
  - **PPMS**, global Ph3 registrational trial, targeting FPI by 2nd half of 2025
  - **SPMS**, global Ph3 registrational trial, targeting FPI by 2nd half of 2025
  - **ITP**, Ph3 registrational trial, targeting NDA submission in 2026H1
  - **SLE**, Ph2b data readout in 2025Q4
- **Soficitinib (ICP-332)** (TYK-2/JAK1)
  - **Atopic dermatitis:** Ph3 registrational trial; patient enrollment is accelerating
  - **Vitiligo:** Ph2 trial initiated; patient enrollment underway
  - **Prurigo Nodularis (PN):** Global Ph2 is being initiated
- **ICP-488** (TYK-2, allosteric) Ph3 registrational trial for **Psoriasis** in China initiated; patient enrollment ongoing

Total Revenue in First Half 2025 Achieved 74.3% yoy Growth, Diversified Portfolio and BD Potential Ensure Continued High Growth

Total Revenue



Drug Sales



- **Total Revenue 74.3% yoy growth**
  - Drug sales continue robust growth
  - R&D engine provides fuel for BD revenue
- **Orelabrutinib 52.8% yoy growth**
  - Only BKTi for high-potential MZL market
  - Enhanced commercial execution to increase market share
- **Diversified portfolio ensures continued high growth**
  - Commercial launch of Tafasitamab for r/r DLBCL in 2nd half 2025
  - Orelabrutinib approved 1L CLL/SLL
  - Zurletrectinib expected approval in 1H2026

Note: The above financials is based on HKFRS (Hongkong Financial Reporting Standards)
Drug Sales include products revenue of orelabrutinib, tafasitamab and other sales

Driving Rapid Top Line Growth, plus Strong Cash Position Provides Flexibility

Loss for the Period

In RMB millions



Loss for the period narrowed down by RMB232M, an 86.7% yoy decrease, attributed to drug sales growth, business collaboration revenue, as well as cost efficiency improvement

R&D Expense

In RMB millions



R&D expenses increased due to strategic investment in our innovative technology platform, expanded resources for prioritized clinical trials, and licensing-in related expenses

Cash and related balance*

In RMB millions

Robust cash and related balance of RMB 7.7B (~US$1.07B) provides flexibility to expedite clinical development and invest in a competitive pipeline

Note: The above financials is based on HKFRS (Hongkong Financial Reporting Standards)
Cash and related balance includes cash and bank balance, other financial assets balance, and interest receivables balance

ICP-B02 (CD3xCD20) Partnership with Prolium

INNOCARE 诺诚健华

康诺亚 Keymed Biosciences

Prolium Bioscience, Inc.

Funded by rtw

Upfront + Near-term Payment + Milestone Payment — **US$ 520M**

Royalty — Tiered Royalties on Net Product Sales

Capitalization and Equity — A Stake in Prolium

Under the terms of the agreement, Prolium will receive the rights to develop and commercialize ICP-B02 in the global non-oncology field and the oncology field outside of Asia.

Orelabrutinib Commercialization:

Driving High Sales Growth through Outstanding Product Data, Expanding Indications and Treatment Areas, and Recommended by Authoritative Guidelines

宜诺凯



Capturing the High-Potential MZL Market

- ✓ **First and only** BTKi for the treatment of r/r MZL
- ✓ MZL: The **second largest** NHL indication with significant market potential
- ✓ Committed to becoming a **market leader in MZL**

Further Expanding the Indications and Market Potential of CLL/SLL and MCL

- ✓ **1L CLL/SLL approved,** further unlocks market potential and is expected to drive significant growth and market penetration
- ✓ **r/r CLL/SLL and r/r MCL approved and included in NRDL**
- ✓ **Prolonging treatment duration** with strong efficacy and safety

Recommended in the 2025 CSCO Lymphoma Guidelines

- ✓ **CLL/SLL:** First-line and r/r CLL/SLL — **Grade I** recommendation
- ✓ **MZL: Grade I** recommendation
- ✓ **MCL:** First-line treatment of MCL — **Grade II** recommendation.

[1]***Indications included in NRDL:*** *adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy (r/r CLL/SLL), adult patients with mantle cell lymphoma who have received at least one prior therapy (r/r MCL), and adult patients with marginal zone lymphoma who have received at least one prior therapy (r/r MZL)*

Orelabrutinib: Strategic Lifecycle Management Driving Future Blockbuster Potential



Innovative Pipeline: Accelerating Portfolio Towards Value Realization

INNOCARE

Pre-IND

ADC
- Solid tumor

IL17 — Oral
- Autoimmune disease

Others — Oral
- Autoimmune disease

Phase 1/2

Mesutoclax (ICP-248) — BCL2
- AML(CHN, Global)
- MDS(CHN, Global)

Soficitinib (ICP-332) — TYK2/JAK1
- Prurigo nodularis (Global) — Phase 2

ICP-189+EGFRi — SHP2
- NSCLC (CHN)

ICP-B02 — CD3XCD20
- NHL (CHN)

ICP-490 — E3 Ligase
- NHL (CHN)

ICP-B05 — CCR8
- Hemato-oncology (CHN)

ICP-B794 — B7H3 ADC
- SCLC

Phase 3

Orelabrutinib — BTK
- TN MCL (CHN)
- MZL confirmatory (CHN)
- ITP (CHN)
- SLE (CHN) — Phase 2b
- PPMS (Global)
- SPMS (Global)

Tafasitimab — CD19
- DLBCL (CHN)

Mesutoclax — BCL2
- TN CLL/SLL-FDT (CHN) — +Orela
- BTKi treated MCL — Phase 2 registrational

Soficitinib (ICP-332) — TYK2/JAK1
- Atopic Dermatitis (CHN)
- Vitiligo (CHN) — Phase 2/3

ICP-488 — TYK-2
- Psoriasis (CHN)

Registration

Orelabrutinib — BTK
- r/r MZL (SG)
- r/r MCL (AU)

Zurletrectinib — NTRK
- NTRK fusion-positive cancers (CHN)

Approved

Orelabrutinib — BTK
- TN CLL/SLL (CHN)
- r/r CLL/SLL (CHN)
- r/r MCL (CHN)
- r/r MCL (SG)
- r/r MZL (CHN)

Tafasitimab — CD19
- r/r DLBCL (Mainland CHN)
- r/r DLBCL (GBA)
- r/r DLBCL (HK)
- r/r DLBCL (Macao)
- r/r DLBCL (TW)

- Hemato-oncology
- Autoimmune Disease
- Solid Tumor

A Leading Hemato-oncology Franchise

Hemato-oncology: Marketed and Phase 3 Clinical Products

Assets	Target	Indication	Clinical Trial	Registration	Market
 Orelabrutinib	BTK	r/r CLL/SLL		★	CHN
		r/r MCL		★	CHN,SG
		r/r MZL		★	CHN
		1L CLL/SLL		★	CHN
		1L MCL	Global Ph3 ongoing		
		MZL Confirmatory Trial	Ph3 ongoing		
 Tafasitamab	CD19	r/r DLBCL		★	
		DLBCL Confirmatory Trial	Ph3 ongoing		
Mesutoclax (ICP-248)	BCL2	1L CLL/SLL-FDT	Ph3 registrational trial ongoing, combo with Orela		
		r/r MCL (BTKi treated)	Registrational trial initiated		
		1L AML	Dose expansion in CHN & global		
		MDS	Global study initiated		
Others (ICP-490, -B02, -B05, etc.)		Hemato-oncology	Clinical trials ongoing in multiple indications		

Marketed

Clinical-Stage

Tafasitamab (CD19): Best Profile Potential for r/r DLBCL, Unlocking Strong Market Potential



Comparison of Selected Novel Therapy in r/r DLBCL

Company	Target	Therapy	Phase	ORR (%)	CR (%)	mDOR (m)	mPFS (m)	mOS (m)
Incyte/ InnoCare	**CD19**	**Tafasitamab + Lenalidomide**	**Approved ex-China**	**57.5**	**40**	**43.9**	**11.6**	**33.5**
ADC Therapeutics	CD19 ADC	Loncastuximab tesirine	**Approved ex-China**	48.3	24.1	10.25	4.93	9.92
Roche	CD79b ADC	Polatuzumab vedotin + BR	**Approved**	42	23	12.6	9.5	12.4
Roche	CD20/ CD3	Glofitamab	BLA	52	39	10.4	3.8	11.5
Amgen/ Beigene	CD19/ CD3	Blinatumomab	II	43	19	11.6	3.7	5.0
Regeneron/ Zai Lab	CD20/ CD3	Mosunetuzumab	II	33	21	N/A	N/A	N/A
AbbVie	BCL-2	Venetoclax+R +Pola	II	65	31	5.8	4.4	11

Non-head-to-head comparison

Source: Cheson BD, et al. Blood Cancer J. 2021;11:68–78.
Frost & Sullivan Analysis as of the end of 2022; Insight; Pharma Intelligence

Tafasitamab (CD19): Best Profile Potential for r/r DLBCL, Robust Clinical Efficacy

- ✓ Greater China's **first CD19-targeted antibody** for **r/r DLBCL**
- ✓ Robust **clinical efficacy**, with high overall response rate and durable remissions demonstrated in pivotal studies
- ✓ Large patient population with high unmet need, as **~40-55%**[1] of DLBCL patients relapse or become refractory after standard therapy
- ✓ Included as a Class II recommended regimen in the **CSCO Guidelines** for adult r/r DLBCL patients ineligible for ASCT
- ✓ **Strong commercial momentum** and first-mover advantage, well-positioned to capture significant market share

With a median follow-up of 44.0 months, the mDOR was not reached[1]



32.7-month median follow-up
5-year DoCR rate estimated at 80.7%[1]



1 Source: Crump M, Cancer Network, 2023; Epperla N, Exp Hematol Oncol, 2023; Cheson BD, ASCO Educ Book, 2023; Xu W, Cancer Commun (Lond), 2021 (CSCO Guidelines)

1.10.3324/haematol.2023.283480

Mesutoclax (ICP-248): A Novel BCL-2 Inhibitor with Great Clinical Advantages



Venetoclax Pharmacological Properties

- M27, a major metabolite of Venetoclax, shows ~80% AUC of the parent drug within 24 h
- M27 has no pharmacological activity but has hematological toxicity*
- Significant inhibition of CYP2C8 and CYP2C9 by Venetoclax and M27 with IC50 ≤ 0.82 μM
- Significant inhibition of P-gp and BCRP by Venetoclax and M27 with IC50 ≤ 1.48 μM

Advantages of Mesutoclax

- Eliminated major metabolite
- Significantly higher exposure
- Reduced hematological toxicity
- Reduced DDI risks
- Excellent efficacy & safety profile

** Venetoclax FDA non-clinical toxicology review*

CYP: Cytochrome P450 proteins; BCRP: breast cancer resistance protein; DDI: drug-drug interaction; PK: Pharmacokinetics

Mesutoclax (ICP-248): Differentiated Profile Driving High Possibility of Success

Ph3 registrational trial Combo with Orelabrutinib for 1L CLL/SLL-FDT ongoing in CHN

Registrational trial ongoing
First BCL-2 inhibitor in China to receive Breakthrough Therapy Designation

BTKi + BCL-2i for 1L CLL/SLL

	Orela+Mesutoclax	Ibru + Ven[1]	Acala + Ven[2]
Sample Size	42	106	291
ORR	100%	86.8%	92.8%
CRR	57.1%*	36.7%	NA
uMRD	65%** W36	45.3% EOT+3	34.4% EOT
TLS	0	0	0.3%

Cutoff date: 2025-07-21

* Complete remission in target lesion at RP3D per image
** MRD checkpoint at 36th week of combo treatment

BTKi-treated MCL

	Mesutoclax	Venetoclax[3,4]	Pirtobrutinib[5]
	BTKi+, N=25	BTKi+, N=17	cBTKi* Pretreated MCL N=90
ORR	84%	53%	57.8%
CRR	36%	18%	20.0%

Cutoff date: 2025-07-10

* cBTKi: covalent Bruton tyrosine kinase inhibitor

1. NEJM Evid 2022;1(7) 2. ASH 2024 3.doi:10.3324/haematol.2018.198812 4.doi.org/10.1182/bloodadvances.2022008916 5.doi:10.1200/JCO.23.00562

Mesutoclax (ICP-248): Advancing AML and MDS Programs with Strong Global Market Potential

1L AML: Dose expansion in CHN & global

MDS: Global study initiated

1L AML

	Mesutoclax	Venetoclax[1]	Lisaftoclax[2]	Sonrotoclax[3]
	N=17	N=286	N=39	N=79
CRR	70%	66.4%	51.3%	67.1%
uMRD*	57.1%	23.5%	NA	52.8%
SAE	5.7%	83%	43.3%	77.2%
60-D Mortality	0%	7% (30-day)	3.9%	3.8% (30-day)

Cutoff date: 2025-07-04

- ✓ **High likelihood of success in MDS**
  Mesutoclax demonstrated robust efficacy and a favorable safety profile, positioning it for a high probability of success in MDS
- ✓ **Large, fast-growing market opportunity**
  The global myelodysplastic syndrome drugs market size was valued at USD 4.55 billion in 2024 and is anticipated to reach around USD 11.17 billion by 2034[4]
- ✓ **Accelerate global clinical studies**
  Optimizing dose and safety in MDS can fast-track global registration trials, strengthening both clinical and commercial positioning

1. N Engl J Med 2020;383:617-29.
2. 2024 ASCO
3. 2025. EHA
4. Nova One Advisor, Insight Code: 8817

Note: *Calculate in patients with composite complete remission

Well Positioned Portfolio in Autoimmune Diseases

Multiple Assets with Large Indications Progressed to Phase 3 Trials

B cell pathway

Orelabrutinib
(BTKi)

- **PPMS** — Global Ph3 registrational trial
- **SPMS** — Global Ph3 registrational trial
- **ITP** — Ph3 registrational trial in CHN
- **SLE** — FIC, Ph2b Data Readout Expected in 2025

T cell pathway

Soficitinib (ICP-332)
(TYK2i/JAK1i)

ICP-488
(TYK2i)

- **AD** — Ph3 registrational trial
- **Vitiligo** — Ph2/3 ongoing
- **PN** — Global Ph2 is being initiated
- **Psoriasis** — Ph3 registrational trial

Others (IL17 small molecule, etc.)

PPMS: Primary Progressive Multiple Sclerosis
SPMS: Secondary Progressive Multiple Sclerosis
ITP: Idiopathic Thrombocytopenic Purpura
SLE: Systemic Lupus Erythematosus
AD: Atopic Dermatitis
PN: Prurigo Nodularis

Orelabrutinib: Enormous Potential for Treating Autoimmune Diseases

宜诺凯
Orelabrutinib

MS

- **PPMS: Global Ph3 ongoing**
- **SPMS: Global Ph3 ongoing**
- With high target selectivity, favorable PK, and the ability to cross the BBB, Orelabrutinib offers a promising therapeutic option for treating PMS
- Best-in-class potential

~2.5 million patients worldwide

ITP

- Ph3 registrational trial for the treatment of ITP is underway in China, with **NDA submission expected in 2026H1**
- BTKi treatment for autoimmune diseases is just around the corner

Over 200,000 new patients globally each year

SLE

- The **world's first and only** BTKi demonstrating efficacy in Ph2 trial
- Ph2b Clinical Trial Enrollment Complete, **Data Readout Expected in 2025Q4**

~8 million patients worldwide

Source: Ehtesham N, et. al. Int Rev Immunol. 2020; 39(6):264–79. , Rarediseases.org, Frost & Sullivan, Sara Bagherieh et. Al. Neurol Sci. 2023 Jun;44(6):1905-1915.

Orelabrutinib in ITP: Large Market Opportunity Approaching NDA

Disease & Patient Population

- ITP (Immune Thrombocytopenia) is a chronic autoimmune bleeding disorder with significant relapse rates after first-line therapy.
- ~300,000 chronic patients in China
- ~60,000 new cases annually

Current Treatment Gaps

Current Therapy	Limitations
Steroids & IVIG	Short-term benefit, significant side effects
TPO-RA	Risk of thrombotic events, decreased efficacy with prolonged treatment
Others	Lack of durable, safe oral options

Orelabrutinib's Advantage

Inhibits abnormal B-cell activation & autoantibody production with wider safety margin and convenient oral dosing

Market Potential

China's large ITP patient base and growing diagnosis rate create a significant market opportunity worth hundreds of millions USD

Key Milestones

2025 H1: Ph3 enrollment completed
2026 H1: NDA filing expected

Poised to address the significant unmet need in ITP – strong potential to become the next growth driver.

Soficitinib (ICP-332), ICP-488: Two Differentiated TYK2 Inhibitors with Great Potential in Multiple Indications

Soficitinib Ph2 AD

Phase 2 data indicates that soficitinib demonstrates significant efficacy in treating AD, showing the best efficacy (placebo-adjusted) compared to several other innovative drugs



 # Not a head-to-head comparison

- ✓ Ph3 registrational trial for AD ongoing
- ✓ Ph2/3 trial for vitiligo ongoing
- ✓ Ph2 global trial for prurigo nodularis is being initiated

ICP-488 Ph2 Psoriasis

ICP-488 demonstrates outstanding efficacy in Ph2 trial for Psoriasis



- ✓ Ph3 registrational trial for psoriasis initiated, patient enrollment ongoing

Oral Therapies for Comprehensive Coverage of Autoimmune Diseases

Orelabrutinib (BTKi)

Soficitinib (ICP-332) (TYK2/JAK1i)

ICP-488 (TYK2i)

IL-17 (small molecule)

Project 40 (cyclic peptide)

Projects 42 & 43 (small molecule)

Project 44 (molecular glue)



Clinical

Pre-clinical

LN: Lupus Nephritis
MN: membranous nephropathy
UC:Ulcerative Colitis
CD: Crohn disease

AA: Aplastic anemia
AIHA: Autoimmune hemolytic anemia
NMO: Neuromyelitis optica
MG:Myasthenia gravis

MoG-EN: MOG antibody-associated encephalomyelitis
SS: Sjogren syndrome
RA: Rheumatoid Arthritis
IgG4 RD:IgG4 related disease

Innovative Solid Tumor Assets

Solid Tumors Strategy

Precision Medicine

Benefit patients more

Zurletrectinib (ICP-723)

- ✓ Second-Generation TRKi for NTRK gene fusion-positive patients registrational trial completed
- ✓ NDA submitted in March 2025, accepted under priority review

Combo Therapy

Benefit more patients

ICP-189 (SHP2i)

- ✓ Dose expansion of combination therapy with Firmonertinib (EGFRi) for NSCLC ongoing

ADC

Targeting Hard-to-Treat Cancers

ICP-B794 (anti-B7-H3 ADC)

- ✓ Innovative linker-payload invented with in-house technology
- ✓ Superior efficacy and safety window in animal models
- ✓ IND approved in July and clinical trial to commence soon
- ✓ PoC in 2025

Design & Advantage of InnoCare's Proprietary ADC Platform

Novel Connector

- Irreversible connector
- Prevent thiol exchange

Hydrophilic Linker

- Allows high DAR
- Improves stability

Effective Payload

- Potent
- Bystander effect
- Tumor-specific release
- Rapid clearance

ICP-B794: Robust Anti-Tumor Activity in Animal Models vs. Other Platforms

ICP-B794 Demonstrates Superior Anti-Tumor Activity in Animal Model Compared to Others

Mouse CDX model



ICP-B794 Exhibits Superior Tumor-killing Effect in Large Tumors

Xenograft CDX model (NSCLC)



Note: linker-payload from different platforms conjugated to InnoCare anti-B7H3, all tested articles with DAR≈8

✓ **Safety Window is >200 fold in preclinical studies**

Zurletrectinib (ICP-723): 2nd Generation TRKi for the Treatment of Tumors with NTRK Gene Abnormalities, NDA accepted under priority review

- Registration trial for NTRK gene abnormalities in adults and adolescents, **NDA accepted under priority review**
  - ✓ **ORR: 85.5%**
  - ✓ Long duration of response (longest beyond 36 months)
  - ✓ Efficacious in TRKi-resistant patients
- Registrational trial for pediatric patients ongoing, **targeting NDA submission in late 2025**

Significant and durable efficacy observed across diverse tumor types in adult patients



Data cut-off：ICP-CL-00505 (2024-06-11); ICP-CL-00501 (2024-04-18)

Key Upcoming Milestones

	Assets	Milestones
Commercialization & BD	Commercialization	Rapid sales growth
	BD	Get more BD deals done
Hemato-oncology	Orelabrutinib	Ph3 registrational trial for combination with ICP-248 in 1L CLL/SLL-FDT complete patient enrollment
	Mesutoclax (ICP-248)	Data readout: Combination with orelabrutinib in 1L CLL/SLL Ph2 trial longer efficacy; BTKi-treated MCL
		Accelerate patient enrollment in registration trial for BTKi-treated MCL
		Aim to get data to support 1L AML registration trial
		Aim to get data to support MDS registration trial
Autoimmune Diseases	Orelabrutinib	Completion of ITP Ph3 registration trial
		Global Ph3 registrational trial initiation in PPMS, FPI
		Global Ph3 registrational trial initiation in SPMS, FPI
		Data readout: SLE Ph2b study
	Soficitinib (ICP-332)	Completion of patient enrollment for Ph3 AD trial
		Completion of patient enrollment for Ph2 vitiligo trial
		Global Ph2 trial in PN, FPI
	ICP-488	Completion of patient enrollment for Ph3 psoriasis trial
Solid Tumor	Zurletrectinib (ICP-723)	NDA approval in adults and adolescents
		Pediatric patients NDA Submission in CHN
	ICP-B794	FPI & Clinical PoC by the end of 2025


SINCE 2015
INNOCARE
Empowering the Future Together
Thank you for your attention !